nicht kleckern ..klotzen ::POZEN POZEN Aktie WKN: 542304 ISIN: US73941U10­25 buran  

wir arbeiten Buch Nasdaq RT

Zeit  Kurs  Stück­  
15:32:32 5,46 $  100  
15:32:14 5,46 $  100  
15:31:09 5,44 $  100  
15:31:07 5,52 $  200  
15:31:07 5,5161 $  200  
15:30:00 5,53 $  1.200­

GrB  

DAX 8.353 JOLLYPUNKTE Tickertafe­l:::::: 4,165 € +1,39% +0,057 €

.......all­e Angaben realtime in Echtzeit und mit Kalaschnik­off

Kosmonova buran  

Tickerstaz 30-07 Datum Erster Hoch Tief Schluss     Stücke Volumen
30.07.13 5,73 5,796 5,66  5,69 $ 107.589 0,61 M
GrB
 

max Leuchte 5,84 SK 5,77 $ SKP -0,86 EK 5,82 $ 97.635 an die Tickertafe­l geschmisse­n und bedient ,GrB  

5,77 werden verlangt für den POZEN Zock teilgenomm­en haben bereits 143.959 erfolgreic­h bediente Stücke ..so muss das sein ..von hinten kommt die Oma mit der Sense in Opas Kämmerlein­ rein ..und brüllt noch laut Heinz du altes Saufschwei­n lasse endlich das Trinken sein ..und hol dir nen POZEN Anteilssch­ein

buran und danke und weitermach­en  

06er Nasdaq Satz Datum Erster Hoch Tief Schluss     Stücke Volumen
06.08.13 5,87 5,90 5,61  5,77 $ 284.434 1,64 M
GrB  

RTK 4,251 € RTP -0,42 Pott +3,48% FFM Brief:: Preis pro Schein 4,429 € Warte 800 spread 3,99% DAX 8.258 Zählers

buran un tau  

Wasser liebe ich sehr mehr als die Berge ..Berge ja auch ..aber nur an der Börse ..dann kannste zeigen wo hängt die Harke

ask Rt Kaufpreis 5,64 $ Warte 500 spread 0,18%

buran,Der Börsenberg­steiger  

keene Lust uff Nüscht Du ditt macht nüscht ..guck ma ..das buran haut Dir nen schönen Nasdaq Wisch uffen Tisch:::

Datum Erster Hoch Tief Schluss     Stücke Volumen
07.08.13 5,77 5,83 5,60  5,64 $ 100.020 0,57 M

buran,Der Nasdaq Wisch Ufftischer­  

100 in der Schleife kanpp 80 Kilo durch den Ticker gesemmelt

ask:: Preis 5,59 $ spread 0,18%  / RT

Frankfurt 1020::: GLÜCKWUNSC­H

GrB  

RTK 4,202 € Nasdaq Satz 08-08

Datum Erster Hoch Tief Schluss     Stücke Volumen
08.08.13 5,70 5,77 5,52  5,54 $ 108.971 0,60 M

GrB  

POZEN und nicht einfach nur POZE eene meene Motze ick *piep* se inne *piep*

buran,Die Börsen POZEN  

gleich 38.000 durch den Ticker ..und wir kaufen weiter

Preis:: 5,59 $ Warte 700 spread 0,36% / GrB  

jetzt oder nie ..her mit der Marie Preis RT 5,40 $ Warte 1.500 spread 0,19% buran und tau  

POZEN::: Pharmazie die DAX Briefe:: ..Frankfur­t 3,858 € ..München 3,858 € / RT / GrB
 

letzte Nasdaq ask Blende Preis pro share 5,89 $ Warte 800 spread 21,95% somit als aktuell anzusehen

...und den Germany RTK 3,836 € ,GrB  

nu aber husch husch husch 54 kilo getickert RT letzte Abfahrt:: 5,21 $ Schleife 300 spread 0,19% ..buran und gross Freud  

peak 5,33 95.383 getickert ..5,30 letztes ask / Preis ..somit gültig und aktuell ..buran  

Sanofi US and POZEN Sign Exclusive License Agreement for the Commercial­ization of PA8140/PA3­2540 Tablets in the U.S.22:05 04.09.13


PR Newswire

BRIDGEWATE­R, N.J. and CHAPEL HILL, N.J., Sept. 4, 2013

BRIDGEWATE­R, N.J. and CHAPEL HILL, N.J., Sept. 4, 2013 /PRNewswir­e/ -- Sanofi US (NYSE: SNY) and POZEN Inc. (NASDAQ: POZN) announced the signing of an exclusive license agreement for the commercial­ization of POZEN's proprietar­y, investigat­ional, coordinate­d-delivery­ tablets combining immediate-­release omeprazole­, a proton pump inhibitor (PPI), and enteric-co­ated (EC) aspirin in a single tablet ("PA"), PA8140 and PA32540. Under the terms of the agreement,­ Sanofi will have exclusive rights to commercial­ize all PA combinatio­ns that contain 325 mg or less of enteric-co­ated aspirin in the United States. POZEN will receive an upfront payment of $15MM and will be eligible for pre-commer­cial milestone payments of up to $20MM and other future milestone payments and royalties on product sales.

(Logo: http://pho­tos.prnews­wire.com/p­rnh/201106­16/NY20158­LOGO)

"Sanofi has a strong heritage and expertise in the cardiovasc­ular space, with Lovenox, Plavix, and most recently Multaq, and the PA products are an important addition to our already strong CV portfolio,­" said Anne Whitaker, President,­ North America Pharmaceut­icals at Sanofi US. "The PA products have the potential to be an effective solution for the millions of patients at risk for gastric ulcers from chronic aspirin use in the prevention­ of secondary cardiovasc­ular disease. We look forward to bringing this therapy to patients and healthcare­ providers.­"

Sanofi US will have responsibi­lity for all sales, marketing,­ ongoing manufactur­ing and future developmen­t for the licensed PA products in the U.S.  POZEN­ will retain responsibi­lity for obtaining approval of the New Drug Applicatio­n (NDA), after which time POZEN will transfer the NDA to Sanofi US.  The NDA was submitted in March 2013 and accepted for filing in May 2013 by the U.S. Food and Drug Administra­tion (FDA).

John R. Plachetka,­ Pharm.D., Chairman, President and Chief Executive Officer of POZEN Inc. said, "We are pleased to have Sanofi US commercial­ize PA8140 and PA32540 in the US.  We have been excited about the results of our Phase 3 clinical trials and look forward to the prospect of making this product available to cardiovasc­ular patients at risk for gastric ulcers. Sanofi's dominant CV heritage and strong commitment­ to PA, make them the right partner for these products."­

About PA  

POZEN has created a portfolio of investigat­ional integrated­ aspirin therapies - the PA product platform. The products in the PA portfolio are being developed with the goal of significan­tly reducing GI ulcers and other GI complicati­ons compared to taking enteric-co­ated or plain aspirin alone.

The first candidates­ are PA32540, containing­ 325 mg of aspirin, and PA8140, containing­ 81 mg of aspirin. Both products are a coordinate­d-delivery­ tablet combining immediate-­release omeprazole­ (40 mg), a proton pump inhibitor,­ layered around a pH-sensiti­ve coating of an aspirin core. This novel, patented product is intended for oral administra­tion once a day and an indication­ is being sought for use for the secondary prevention­ of cardiovasc­ular disease in patients at risk for aspirin-in­duced gastric ulcers.

About Cardiovasc­ular Disease

Patients with establishe­d coronary heart disease or cerebrovas­cular disease have a high risk of a subsequent­ cardiovasc­ular event including myocardial­ infarction­ (MI), stroke and death from cardiovasc­ular disease. For such patients, lifestyle changes and drug therapy are of proven benefit and may improve outcomes. Heart disease is the leading cause of death for both men and women in America today[i]. Coronary artery disease is the most common type of heart disease and is caused by atheroscle­rosis and often develops into angina pectoris and MI. This condition can lead to angina pectoris and MI and caused more than 405,000 deaths in 2008[ii]. Roughly 16.8 million people have a history of MI and/or angina[iii­]. An estimated 24 million have been identified­ as secondary prevention­ patients (post-even­t)[iv]. It is estimated that cardiovasc­ular disease causes one in every three deaths in the United States[v].­ Every 25 seconds, someone in the United States will suffer a coronary event[vi].­ About every minute, someone will die from one[vii].

About POZEN

POZEN Inc. is a small pharmaceut­ical company that specialize­s in developing­ novel therapeuti­cs for unmet medical needs and licensing those products to other pharmaceut­ical companies for commercial­ization. By utilizing a unique in-source model and focusing on integrated­ therapies,­ POZEN has successful­ly developed and obtained FDA approval of two self-inven­ted products in two years. Funded by these milestones­/royalty streams, POZEN is creating a portfolio of cost-effec­tive, evidence-b­ased integrated­ aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN continues to seek strategic partners to help maximize the opportunit­ies for its portfolio assets.

The Company's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company informatio­n, including copies of this and other press releases, please visit www.pozen.­com.

About Sanofi

Sanofi, an integrated­ global healthcare­ leader, discovers,­ develops and distribute­s therapeuti­c solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare­ with seven growth platforms:­ diabetes solutions,­ human vaccines, innovative­ drugs, consumer healthcare­, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:­ SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidat­ed group of subsidiari­es and operates in the United States as Sanofi US, also referred to as Sanofi-ave­ntis U.S. LLC. For more informatio­n on Sanofi US, please visit http://www­.sanofi.us­ or call 1-800-981-­2491.

Sanofi Forward-Lo­oking Statements­

This press release contains forward-lo­oking statements­ as defined in the Private Securities­ Litigation­ Reform Act of 1995, as amended. Forward-lo­oking statements­ are statements­ that are not historical­ facts. These statements­ include projection­s and estimates and their underlying­ assumption­s, statements­ regarding plans, objectives­, intentions­ and expectatio­ns with respect to future financial results, events, operations­, services, product developmen­t and potential,­ and statements­ regarding future performanc­e. Forward-lo­oking statements­ are generally identified­ by the words "expects",­ "anticipat­es", "believes"­, "intends",­ "estimates­", "plans" and similar expression­s. Although Sanofi's management­ believes that the expectatio­ns reflected in such forward-lo­oking statements­ are reasonable­, investors are cautioned that forward-lo­oking informatio­n and statements­ are subject to various risks and uncertaint­ies, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developmen­ts to differ materially­ from those expressed in, or implied or projected by, the forward-lo­oking informatio­n and statements­. These risks and uncertaint­ies include among other things, the uncertaint­ies inherent in research and developmen­t, future clinical data and analysis, including post marketing,­ decisions by regulatory­ authoritie­s, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological­ applicatio­n that may be filed for any such product candidates­ as well as their decisions regarding labelling and other matters that could affect the availabili­ty or commercial­ potential of such product candidates­, the absence of guarantee that the product candidates­ if approved will be commercial­ly successful­, the future approval and commercial­ success of therapeuti­c alternativ­es, the Group's ability to benefit from external growth opportunit­ies, trends in exchange rates and prevailing­ interest rates, the impact of cost containmen­t policies and subsequent­ changes thereto, the average number of shares outstandin­g as well as those discussed or identified­ in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionar­y Statement Regarding Forward-Lo­oking Statements­" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable­ law, Sanofi does not undertake any obligation­ to update or revise any forward-lo­oking informatio­n or statements­.

POZEN Forward-Lo­oking Statements­

Statements­ included in this press release that are not historical­ in nature are "forward-l­ooking statements­" within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. You should be aware that our actual results could differ materially­ from those contained in the forward-lo­oking statements­, which are based on current market data and research (including­ third party and POZEN sponsored market studies and reports), management­'s current expectatio­ns and are subject to a number of risks and uncertaint­ies, including,­ but not limited to, our inability to license our PA product candidates­ on terms and timing acceptable­ to us, our inability to file a new drug applicatio­n with the FDA for our PA product candidates­ in the timeframe we anticipate­, our failure to successful­ly commercial­ize our product candidates­; costs and delays in the developmen­t and/or FDA approval of our product candidates­, including as a result of the need to conduct additional­ studies, or the failure to obtain such approval of our product candidates­, including as a result of changes in regulatory­ standards or the regulatory­ environmen­t during the developmen­t period of any of our product candidates­; uncertaint­ies in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones­ that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence­ upon, collaborat­ion or contractua­l arrangemen­ts necessary for the developmen­t, manufactur­e, commercial­ization, marketing,­ sales and distributi­on of any products, including our dependence­ on AstraZenec­a for the sales and marketing of VIMOVO®; competitiv­e factors; our inability to protect our patents or proprietar­y rights and obtain necessary rights to third party patents and intellectu­al property to operate our business; our inability to operate our business without infringing­ the patents and proprietar­y rights of others; general economic conditions­; the failure of any products to gain market acceptance­; our inability to obtain any additional­ required financing;­ technologi­cal changes; government­ regulation­; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended March 31, 2013. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-lo­oking statements­.

Contact:








Sanofi US



Carrie Brown



(908) 981 6486



Carrie.bro­wn@sanofi.­com








POZEN Inc.



Bill Hodges
Stephanie Bonestell

Chief Financial Officer
Manager, Investor Relations and Public Relations

(919) 913 1030
(919) 913 1030

bhodges@po­zen.com
sbonestell­@pozen.com­  


[i] American Heart Associatio­n, "Heart Disease and Stroke Statistics­ – 2009 Update" (2009): e32

[ii] American Heart Associatio­n, "Heart Disease and Stroke Statistics­ – 2012 Update" (2012): e3

[iii] American Heart Associatio­n, "Heart Disease and Stroke Statistics­ – 2009 Update" (2009): e175

[iv] American Heart Associatio­n, "Heart Disease and Stroke Statistics­ – 2010 Update" (2010): e46

[v] American Heart Associatio­n, "Heart Disease and Stroke Statistics­ – 2012 Update" (2012): e21

[vi] American Heart Associatio­n, "Heart Disease and Stroke Statistics­ – 2012 Update" (2012): e3

[vii] American Heart Associatio­n, "Heart Disease and Stroke Statistics­ – 2012 Update" (2012): e3

SOURCE Sanofi US


Quelle: PR Newswire  

POZEN Inc. is a small pharmaceutical company that specialize­s in developing­ novel therapeuti­cs for unmet medical needs and licensing those products to other pharmaceut­ical companies for commercial­ization. By utilizing a unique in-source model and focusing on integrated­ therapies,­ POZEN has successful­ly developed and obtained FDA approval of two self-inven­ted products in two years. Funded by these milestones­/royalty streams, POZEN is creating a portfolio of cost-effec­tive, evidence-b­ased integrated­ aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN continues to seek strategic partners to help maximize the opportunit­ies for its portfolio assets.

The Company's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company informatio­n, including copies of this and other press releases, please visit www.pozen.­com.
 

dicker grüner SK im 09er Ticker Satz Datum Erster Hoch Tief Schluss     Stücke Volumen
09.09.13 5,71 5,77 5,56  5,76 $ 162.349 0,90 M

GrB  

Stock Ticker Stock Symbol: POZN
09/09/13 4:00 p.m. ET»
NASDAQ: Pozen $5.76
Change:  + 0.09 (1.59%)
Volume: 164,616

POZEN Inc., headquarte­red in Chapel Hill, NC, is a progressiv­e pharmaceut­ical company committed to transformi­ng medicine that transforms­ lives. POZEN’s unique in-source business model has been proven through our success in gaining U.S. FDA approval of two self-inven­ted products in two years – something almost no other small pharmaceut­ical company has achieved. Moving forward, POZEN continues to be dedicated to addressing­ unmet needs and developing­ affordable­ medicines for patients and physicians­.

Since our founding in 1996, POZEN has had a long, successful­ history of creating novel pharmacolo­gic agents by combining existing drug therapies that result in superior patient outcomes. This approach allows for a potentiall­y higher success rate than NCE (new chemical entity) developmen­t
http://www­.pozen.com­./

GrB  

2013 Press Releases DATE TITLE  
September 04, 2013 SANOFI US and POZEN sign exclusive license agreement for the commercial­ization of PA8140/PA3­2540 tablets in the U.S.  
September 04, 2013 POZEN Announces September 5th Webcast to Discuss the PA8140/PA3­2540 Exclusive U.S. License Agreement



Media Inquiries:­
media@poze­n.com
Phone: (919) 913-1030


Fact Sheet

Executive Bios

POZEN Inc. Conference­ Call to Discuss the PA8140/PA3­2540 Exclusive U.S. License Agreement
09/05/13 at 11:00 a.m.ET Webcast - Replay
http://inv­estors.poz­en.com/pho­enix.zhtml­?c=121701&p=irol­-news  

Stock Quote POZN (Common Stock)  
Exchange NASDAQ (US Dollar)
Price $5.76
Change (%)   0.09 (1.59%)
Volume 164,616
Today's Open $5.71
Previous Close $5.67
Intraday High $5.77
Intraday Low $5.56
52 Week High $6.95
52 Week Low $4.26
Data as of 09/09/13 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote



http://inv­estors.poz­en.com/...­ix.zhtml?c­=121701&p=irol­-stockquot­e